Currently, more than 400 studies worldwide focus on PD-L1/PD-1 immune checkpoint signaling, including 65 studies for cancer of the gastrointestinal tract [7], and there is some evidence that PD-L1 expression is associated with response to PDL-1/PD-1 pathway inhibition [8]. Here, PDCD1 is linked to cancer.